PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex

Defining the role of epigenetic regulators in hematopoiesis has become critically important, because recurrent mutations or aberrant expression of these genes has been identified in both myeloid and lymphoid hematological malignancies. We found that PRMT4, a type I arginine methyltransferase whose function in normal and malignant hematopoiesis is unknown, is overexpressed in acute myelogenous leukemia patient samples. Overexpression of PRMT4 blocks the myeloid differentiation of human stem/progenitor cells (HSPCs), whereas its knockdown is sufficient to induce myeloid differentiation of HSPCs. We demonstrated that PRMT4 represses the expression of miR-223 in HSPCs via the methylation of RUNX1, which triggers the assembly of a multiprotein repressor complex that includes DPF2. As part of the feedback loop, PRMT4 expression is repressed posttranscriptionally by miR-223. Depletion of PRMT4 results in differentiation of myeloid leukemia cells in vitro and their decreased proliferation in vivo. Thus, targeting PRMT4 holds potential as a novel therapy for acute myelogenous leukemia.

The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation

The chromosomal translocations found in acute myelogenous leukemia (AML) generate oncogenic fusion transcription factors with aberrant transcriptional regulatory properties. Although therapeutic targeting of most leukemia fusion proteins remains elusive, the posttranslational modifications that control their function could be targetable. We found that AML1-ETO, the fusion protein generated by the t(8;21) translocation, is acetylated by the transcriptional coactivator p300 in leukemia cells isolated from t(8;21) AML patients, and that this acetylation is essential for its self-renewal-promoting effects in human cord blood CD34(+) cells and its leukemogenicity in mouse models. Inhibition of p300 abrogates the acetylation of AML1-ETO and impairs its ability to promote leukemic transformation. Thus, lysine acetyltransferases represent a potential therapeutic target in AML.

Production of auto-anti-idiotype antibody during the normal immune response. XIV. Evidence for the antigen-independent operation of the idiotype network

We have previously shown that that idiotype (Id) repertoire expressed by old mice is different from that of young mice after immunization with trinitrophenylated Ficoll. Older mice also produce more auto-anti-Id antibodies than do young mice. Mice surviving a normally lethal dose of radiation (800 rads) as result of partial shielding of their bone marrow slowly recover immune function, after the repopulation of their peripheral lymphoid system by bone marrow precursor cells. Aged mice subjected to such a procedure produce low auto-anti-Id responses, like those of young mice. However, transfer of splenic T cells from old donors into such mice increases the magnitude of the auto-anti-Id response. In the present studies, we show that the age-related shift in Id expression is also determined by the age of the donor T cells. Furthermore, we show in serial cell transfer studies that the peripheral T-cell population of old mice modifies the level of the auto-anti-Id response in the absence of antigen. The results thus provide evidence for the normal, in vivo, operation of an Id-anti-Id network between B and T lymphocytes.